Lori Mercurio Joins NorthStar Medical Radioisotopes, LLC as Vice President, Corporate Strategy and Business Development

BELOIT, Wis., April 22, 2025 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced that Lori Mercurio has joined the company as Vice President, Corporate Strategy and Business Development. In this role, Mercurio will be responsible for conducting market and competitive research to identify growth opportunities and developing and implementing long-term strategic plans to help NorthStar achieve its overarching goals and objectives. Mercurio will also lead the company’s business development activities; identifying, pursuing and evaluating promising opportunities to grow NorthStar’s portfolio.

Mercurio brings more than 25 years of strategy, business development and operations management experience to NorthStar. Prior to joining North Star, she served in executive roles of increasing responsibility leading strategy and business development initiatives in Specialty Pharmaceuticals and contract development and manufacturing operations (CDMO) businesses. In addition to strategy and business development work, her career has included R&D, procurement, and quality roles.

Commenting on Mercurio’s appointment, Frank Scholz, President and CEO of NorthStar Medical Radioisotopes said, “Lori brings a wealth of relevant direct experience to NorthStar and is deeply versed in assessing opportunities and strategic challenges in pharmaceutical/biopharmaceutical and CDMO industries. As the radiopharmaceutical sector grows in impact and influence, Lori’s skills in partnerships and collaborative ventures will be powerful in supporting our growth. She is a strong addition to our leadership team.”

Commenting on joining NorthStar, Mercurio said, “I am excited by the surge in innovation and funding in the radiopharmaceutical market because I believe it gives us a unique opportunity to be part of developing life-saving therapies for cancer patients. And as a company, I find NorthStar particularly compelling. Our integrated service offering of isotope-drug development and manufacturing services provides real value to drug innovators and significantly advances the field. The company has benefited from smart and sustained investment, and is well positioned to win.”

Mercurio has a Master of Business Administration degree from Washington University-St. Louis, a Master’s Degree in Quality Management from Webster University, and a Bachelor of Science degree in Biology from the University of Missouri St Louis.

About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces copper-67 (Cu-67) and is poised to be one of the first commercial-scale producers of non-carrier added actinium-225 (n.c.a. Ac-225). The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar’s comprehensive portfolio and patient-focused services. Visit: www.northstarnm.com.

NorthStar Medical Radioisotopes, LLC Contact:
Corporate:
Alison Hess
Vice President, Chief of Staff
608-295-9806
[email protected]